Immunogenicity of Fractional Dose of the HPV Vaccines

Summary

This randomized phase IV trial compares intramuscular and intradermal fractional dose of bivalent HPV vaccine to fractional dose of nonavalent HPV vaccine among men and women aged 27-45 years in Seattle, Washington. Participants will have immune response assessed at baseline, 4 weeks, 6 months, and 12 months

Timeline

Start

2022-06-15

Primary completion

2026-12-31

Completion

2026-12-31

Drugs

Indications